Related Experiment Video
Updated: Feb 15, 2026

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
Published on: June 4, 2017
Glioblastoma under Siege: An Overview of Current Therapeutic Strategies
Mayra Paolillo1, Cinzia Boselli2, Sergio Schinelli3
1Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy. mayra.paolillo@unipv.it.
Abstract:
Glioblastoma is known to be one of the most lethal and untreatable human tumors. Surgery and radiotherapy in combination with classical alkylating agents such as temozolomide offer little hope to escape a poor prognosis. For these reasons, enormous efforts are currently devoted to refine in vivo and in vitro models with the specific goal of finding new molecular aberrant pathways, suitable to be targeted by a variety of therapeutic approaches, including novel pharmaceutical formulations and immunotherapy strategies. In this review, we will first discuss current molecular classification based on genomic and transcriptomic criteria. Also, the state of the art in current clinical practice for glioblastoma therapy in the light of the recent molecular classification, together with ongoing phases II and III clinical trials, will be described. Finally, new pharmaceutical formulations such as nanoparticles and viral vectors, together with new strategies entailing the use of monoclonal antibodies, vaccines and immunotherapy agents, such as checkpoint inhibitors, will also be discussed.
Insights
Glioblastoma remains a deadly cancer with limited treatment options. This review explores new molecular targets and advanced therapies, including immunotherapy and novel drug delivery systems, to improve patient outcomes.
Area of Science:
- Neuro-oncology
- Genomics and Transcriptomics
- Cancer Therapeutics
Background:
- Glioblastoma is a highly lethal and difficult-to-treat human brain tumor.
- Current treatments like surgery, radiotherapy, and temozolomide offer limited efficacy.
- There is a critical need for novel therapeutic strategies and improved models for glioblastoma research.
Purpose of the Study:
- To review the current molecular classification of glioblastoma based on genomic and transcriptomic data.
- To describe the current clinical practice and ongoing clinical trials for glioblastoma therapy.
- To discuss emerging therapeutic approaches, including novel pharmaceutical formulations and immunotherapy.
Main Methods:
- Literature review of current glioblastoma research and clinical practice.
- Analysis of genomic and transcriptomic data for molecular classification.
- Discussion of novel therapeutic strategies and formulations.
Main Results:
- Glioblastoma classification is evolving with genomic and transcriptomic insights.
- Current therapies have limited success, highlighting the need for new approaches.
- Emerging treatments include nanoparticles, viral vectors, monoclonal antibodies, vaccines, and checkpoint inhibitors.
Conclusions:
- Refined molecular classification is crucial for targeted glioblastoma therapy.
- Novel pharmaceutical formulations and immunotherapy represent promising avenues for treatment.
- Continued research into molecular pathways and advanced therapies is essential to improve glioblastoma prognosis.
Related Concept Videos
Controlled-Current Coulometry: Overview
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Index
Electrical Current
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Current Density

